HighMark Wealth Management’s Aldeyra Therapeutics ALDX Stock Holding History

HighMark Wealth Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330	Hold	155	–	–	﹤0.01%	528
2026 Q1	$261	Hold	155	–	–	﹤0.01%	526
2025 Q4	$802	Hold	155	–	–	﹤0.01%	520
2025 Q3	$809	Hold	155	–	–	﹤0.01%	537
2025 Q2	$594	Hold	155	–	–	﹤0.01%	550
2025 Q1	$891	Hold	155	–	–	﹤0.01%	496
2024 Q4	$773	Hold	155	–	–	﹤0.01%	506
2024 Q3	$835	Hold	155	–	–	﹤0.01%	524
2024 Q2	$513	Hold	155	–	–	﹤0.01%	535
2024 Q1	$507	Hold	155	–	–	﹤0.01%	525
2023 Q4	$544	Hold	155	–	–	﹤0.01%	533
2023 Q3	$1.03K	Hold	155	–	–	﹤0.01%	503
2023 Q2	$1.3K	Hold	155	–	–	﹤0.01%	489
2023 Q1	$1.54K	Hold	155	–	–	﹤0.01%	522
2022 Q4	$1.08K	Hold	155	–	–	﹤0.01%	468
2022 Q3	$1K	Sell	155 -610	-80%	-$3.66K	﹤0.01%	455
2022 Q2	$3K	Sell	765 -2,000	-72%	-$6.88K	﹤0.01%	388
2022 Q1	$12K	Sell	2,765 -350	-11%	-$1.39K	0.01%	234
2021 Q4	$12K	Sell	3,115 -1,442	-32%	-$11K	0.01%	230
2021 Q3	$40K	Buy	4,557 +197	+5%	+$1.81K	0.03%	129
2021 Q2	$49K	Buy	4,360 +3,501	+408%	+$42.1K	0.04%	115
2021 Q1	$10K	Buy	+859	New	+$9.89K	0.01%	229

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

HighMark Wealth Management's ALDX Position: Q2 2026 in Review

HighMark Wealth Management held its Aldeyra Therapeutics (ALDX) position steady in Q2 2026 at 155 shares worth $330. The position accounts for ﹤0.01% of the portfolio, ranked #528.

HighMark Wealth Management first reported a position in ALDX in Q1 2021 and has held it in 22 quarters since. The position peaked at $49K in Q2 2021. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

HighMark Wealth Management held 155 shares of Aldeyra Therapeutics worth $330 as of Q2 2026.
HighMark Wealth Management left its Aldeyra Therapeutics share count unchanged in Q2 2026.
Aldeyra Therapeutics made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #528 holding.
HighMark Wealth Management first reported a position in Aldeyra Therapeutics in Q1 2021 and has held it in 22 quarters since.
HighMark Wealth Management's Aldeyra Therapeutics position peaked at $49K in Q2 2021.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.